Ferozsons Subsidiary Launches New Insulin Medicine to Combat Diabetes

BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited (PSX: FEROZ), has successfully launched human insulin under the brand name “Ferulin”. “This launch marks a significant milestone in our commitment to STOP DIABETES, expand our product portfolio and enhance the availability of life-saving medicines in the market. Ferulin has been developed with the highest quality standards and is intended to provide effective and affordable diabetes treatment to patients across Pakistan,” the company told the main bourse on Thursday. Being the 1st Biotech Plant in Pakistan, BF Biosciences Limited has been committed to producing essential medicines for treating HCV, Cancer, Cardiology and other therapeutic areas for over a decade. “We are confident that Ferulin will positively impact our subsidiary’s growth and will further strengthen our mission to address unmet patient needs,” the filing added. This comes just over a week after BF Biosciences Limited applied for listing on the Main Board of PSX. BF Bioscience is a pioneering joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina was founded in 2006 as Pakistan’s first CGMP biotech formulation company.